MxA protein induction in MS patients treated with intramuscular IFNβ-1a

Neurological Sciences

Volumn 26, Issue 6, 2006, Pages 438-443

  Vallittu, Anna Maija ^a   Salmi, A A ^a   Erälinna, Juha Peka ^a,c   Elovaara, Irina ^b   Färkkilä, Markus ^d   Kinnunen, Esko ^e   Baumann, Peter ^f   Koivisto, Keijo ^g   Oksaranta, Olli ^h   Pammo, Osmo ⁱ   Reunanen, Mauri ^j   Ruutiainen, Juhani ^k  

^a UNIVERSITY OF TURKU   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e Hospital of Hyvinkää   (Finland)

^f LAPLAND CENTRAL HOSPITAL   (Finland)

^g SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^h District Hospital of Vakka Suomi   (Finland)

ⁱ PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^j OULU UNIVERSITY HOSPITAL   (Finland)

^k Maskun Neurologinen Kuntoutuskeskus   (Finland)

more..

Author keywords

Interferon beta; Multiple sclerosis; MxA; Neutralising antibodies

Indexed keywords

BETA1A INTERFERON; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY;

ADULT; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; BIOLOGICAL ACTIVITY; CHRONIC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HUMAN; LEUKOCYTE; LYMPHOCYTE; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDY; PROTEIN INDUCTION; PROTEIN SYNTHESIS; RELAPSE; REMISSION; TREATMENT DURATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; DISABILITY EVALUATION; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENE EXPRESSION; GTP-BINDING PROTEINS; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 33645656086     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-006-0529-7     Document Type: Article

References (19)

1. IFN beta multiple sclerosis study group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: Clinical results of a multi-center, randomised, doubleblind, placebo-controlled trial. Neurology 43:655-661
2. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) study group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 352:1498-1504
3. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) study group; and the University of British Columbia MS/MRI analysis group. PRISMS-4 (2001) Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628-1636
4. Panitch H, Goodin DS, Francis G et al (2002) Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE Trial. Neurology 59:1496-1506
5. Clanet M, Radue EW, Kappos L et al (2002) A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 59:1507-1517
6. The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI analysis group (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45:1277-1285
7. Deisenhammer F, Mayringer I, Harvey J et al (2000) A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 54:2055-2060
8. Vallittu AM, Halminen M, Peltoniemi J et al (2002) Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a treated MS patients. Neurology 58:1786-1790
9. Abdul-Ahad AK, Galazka AR, Revel M et al (1993) Incidence of antibodies to interferon-β in patients treated with recombinant human interferon-b1a from mammalian cells. Cytokines Cell Mol Ther 3:27-32
10. Halminen M, Ilonen J, Julkunen I et al (1997) Expression of MxA protein in blood lymphocytes discriminates between viral and bacterial infections in febrile children. Pediatr Res 41:647-650
11. Bertolotto A, Malucchi S, Sala A et al (2002) Differential effects of three interferon betas on neutralizing antibodies in patients with multiple sclerosis: A follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73:148-153
12. Bertolotto A, Gilli F, Sala A et al (2003) Persistent neutralizing antibodies abolish the interferon-β bioavailability in MS patients. Neurology 60:634-639
13. Gilli F, Marnetto M, Caldano A et al (2005) Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 158:195-203
14. Pachner AR, Dail D, Park E, Narayan K (2005) The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodies. J Neuroimmunol 166:180-188
15. Ronni T, Melén K, Malygin A, Julkunen I (1993) Control of IFN-inducible MxA gene expression in human cells. J Immunol 150:1715-1726
16. Williams GJ, Witt PL (2002) Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and Avonex. J Interferon Cytokine Res 18:967-975
17. Bertolotto A, Sala A, Malucchi S et al (2004) Biological activity if interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralizing antibodies. J Neurol Neurosurg Psychiatry 75:1294-1299
18. Rothuizen LE, Buclin T, Spertini F et al (1999) Influence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 99:131-141
19. Dupont SA, Goelz S, Goyal J, Green M (2002) Mechanisms for regulation of cellular responsiveness to human IFNβ-1a. J Interferon Cytokine Res 22:491-501